Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo Controlled, Randomized, Adaptive, First-in-Human Study to Assess, Safety, Tolerability, Pharmacokinetics and Food Effect of Single and Multiple Doses of BLU-5937 Administered Orally in Healthy Male and Female

Trial Profile

A Double-Blind, Placebo Controlled, Randomized, Adaptive, First-in-Human Study to Assess, Safety, Tolerability, Pharmacokinetics and Food Effect of Single and Multiple Doses of BLU-5937 Administered Orally in Healthy Male and Female

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs BLU-5937 (Primary)
  • Indications Cough
  • Focus Adverse reactions; First in man
  • Sponsors BELLUS Health
  • Most Recent Events

    • 19 Nov 2018 Results presented in a BELLUS Health media release.
    • 08 Nov 2018 Status changed from recruiting to completed.
    • 27 Jun 2018 According to a BELLUS Health media release, the study is expected to initiate in July 2018, with results expected in the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top